ストックスクリーナーアプリを入手
35.26
1.84%
-0.66
前日終値:
$35.92
開ける：
$36.01
24時間の取引高:
564.23K
Relative Volume:
0.45
時価総額：
$4.12B
収益：
$22.57M
当期純損益:
$-212.73M
株価収益率:
-19.54
EPS:
-1.8045
ネットキャッシュフロー:
$-142.19M
1週間 パフォーマンス:
+1.23%
1か月 パフォーマンス:
+20.22%
6か月 パフォーマンス:
+2.59%
1年 パフォーマンス:
+60.13%
1日の値動き範囲:
$34.15
$36.17
1週間の範囲:
$33.81
$37.37
52週間の値動き範囲:
$20.53
$42.20
Newamsterdam Pharma Company Nv Stock (NAMS) Company Profile
Compare NAMS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NAMS
Newamsterdam Pharma Company Nv
|
35.26 | 4.12B | 22.57M | -212.73M | -142.19M | -1.8045 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Newamsterdam Pharma Company Nv Stock (NAMS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-18 | 開始されました | Truist | Buy |
| 2025-10-20 | 再開されました | H.C. Wainwright | Buy |
| 2025-08-25 | 開始されました | Wells Fargo | Overweight |
| 2025-07-17 | 開始されました | Goldman | Neutral |
| 2025-06-17 | 開始されました | Citigroup | Buy |
| 2025-06-10 | 開始されました | Stifel | Buy |
| 2025-06-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-30 | 開始されました | H.C. Wainwright | Buy |
| 2024-05-15 | 開始されました | TD Cowen | Buy |
| 2024-03-14 | 開始されました | Scotiabank | Sector Outperform |
| 2024-01-18 | 開始されました | Guggenheim | Buy |
| 2024-01-16 | 開始されました | Piper Sandler | Overweight |
| 2023-10-30 | 開始されました | RBC Capital Mkts | Outperform |
すべてを表示
Newamsterdam Pharma Company Nv (NAMS) 最新ニュース
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Responsive Playbooks and the NAMS Inflection - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Alzheimer’s Data Push Puts Fair Value Back In Focus - Sahm
NAMSNewAmsterdam Pharma Company NV Latest SEC Filings - Finviz
(NAMSW) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
NewAmsterdam Pharma awards stock incentives to four new hires - Stock Titan
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026 - marketscreener.com
NewAmsterdam Pharma Company N.V. - TradingView
NewAmsterdam Pharma puts obicetrapib in Alzheimer’s spotlight at AAIC 2026 - Stock Titan
Price to sales forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – BOATS:NAMSW - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to sales forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMSW - TradingView
Understanding the Setup: (NAMS) and Scalable Risk - Stock Traders Daily
Price to book forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Price to book forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (NASDAQ:NAMS) - TradingView
NAMS Forecast — Price Target — Prediction for 2027 - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (MUN:KH6) - TradingView
Enterprise value to EBITDA forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
Enterprise value to revenue forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company N.V. Actuals & Estimates (LSX:A3DUAC) - TradingView
Enterprise value to EBIT forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) Slides 2.76% as Stock Tests Key Support LevelsRounding Bottom - dars.gov.et
Price to earnings forward of NewAmsterdam Pharma Company N.V. – NASDAQ:NAMS - TradingView
NewAmsterdam Pharma (NAMS) CAO exercises options and sells 40,000 shares - Stock Titan
Price to earnings forward of NewAmsterdam Pharma Company N.V. – LSX:A3DUAC - TradingView
NewAmsterdam Pharma Company NV (NAMS) Institutional Confidence - TradingKey
Breakeven On The Horizon For NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) - Moomoo
NewAmsterdam Pharma Company NV (NAMS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company (NAMS) Proxy filing Summary - Quartr
NAMS News | NEWAMSTERDAM PHARMA CO NV (NASDAQ:NAMS) - ChartMill
NewAmsterdam Pharma Company NV (NAMSW) Institutional Confidence - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
NewAmsterdam Pharma Company NV - TradingKey
NewAmsterdam Pharma Company NV (NAMSW) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Valuation: PE, PB & Fair Value Analysis - TradingKey
NewAmsterdam Pharma Company NV (NAMS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
The Technical Signals Behind (NAMS) That Institutions Follow - Stock Traders Daily
NewAmsterdam Pharma (NAMS) Slides 1.26% Amidst Cautious Trading, Support at $28.7 HoldsVol Target Rebalance - newsline.com
NAMSW SEC FilingsNewAmsterdam Pha 10-K, 10-Q, 8-K Forms - Stock Titan
Newamsterdam Pharma Company Nv (NAMS) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):